Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Scholar Rock Holding Corporation - Common Stock
(NQ:
SRRK
)
37.41
+7.34 (+24.41%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Scholar Rock Holding Corporation - Common Stock
< Previous
1
2
3
4
5
6
Next >
Top movers analysis one hour before the close of the markets on 2025-11-14: top gainers and losers in today's session.
↗
November 14, 2025
Here are the top movers in Friday's session, showcasing the stocks with significant price changes.
Via
Chartmill
Why Is Scholar Rock Holding Stock Climbing Today?
↗
November 14, 2025
Scholar Rock shares jump after the company strengthened its cash runway into 2027 and advanced launch preparations for its lead drug candidate, apitegromab.
Via
Benzinga
Why Did Scholar Rock Soar 26% Today?
↗
November 14, 2025
The company is planning to reapply for approval of a muscle atrophy therapy in the coming year.
Via
Stocktwits
Topics
Earnings
Gold Tumbles Over 2%; Cidara Therapeutics Shares Spike Higher
↗
November 14, 2025
Via
Benzinga
Scholar Rock In Spotlight After FDA Refuses To Approve Muscular Atrophy Treatment Over Third-Party Manufacturing Facility Issues
↗
September 23, 2025
Via
Stocktwits
Let's uncover which stocks are experiencing notable gaps during today's session.
↗
November 14, 2025
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday.
Via
Chartmill
Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday
↗
November 14, 2025
Via
Benzinga
Scholar Rock Holding Corp (NASDAQ:SRRK) Posts Wider-Than-Expected Q3 2025 Loss Amid Key Launch Preparations
↗
November 14, 2025
Scholar Rock invests heavily in its lead drug apitegromab, targeting a 2026 launch for spinal muscular atrophy despite a wider Q3 2025 loss.
Via
Chartmill
Looking For A Squeeze? Here Are The Top 10 Most Shorted Stocks
↗
November 13, 2025
Lucid, Avis, Hims & Hers Health and Upstart are some of the most heavily shorted stocks right now. Here's a look at the top ten.
Via
Benzinga
Earnings Scheduled For November 14, 2025
↗
November 14, 2025
Via
Benzinga
What to Expect from Scholar Rock Holding's Earnings
↗
November 13, 2025
Via
Benzinga
3 Beaten-Down Stocks With Rebound Potential This Earnings Season
↗
November 12, 2025
Via
MarketBeat
Alpha Buying: 3 Stocks With Sky-High Insider Confidence
↗
October 14, 2025
Via
Benzinga
Why Scholar Rock Stock Got Socked on Monday
↗
October 13, 2025
The biotech suffered a regulatory setback last month, and this new development might be another blow to its prospects.
Via
The Motley Fool
Topics
Earnings
Why Is Scholar Rock Stock Trading Lower On Monday?
↗
October 13, 2025
Scholar Rock stock falls as FDA issues Form 483 to Catalent; company to meet FDA, while apitegromab shows lean mass preservation in trial.
Via
Benzinga
Why Are Regeneron And Scholar Rock Shares Falling On Monday?
↗
October 13, 2025
Regeneron and Scholar Rock’s submissions have been delayed or denied following an FDA inspection at the third-party fill-finish facility Catalent Indiana, owned by Novo Nordisk.
Via
Stocktwits
12 Health Care Stocks Moving In Monday's Intraday Session
↗
October 13, 2025
Via
Benzinga
There are notable gap-ups and gap-downs in today's session.
↗
October 13, 2025
Via
Chartmill
Fastenal Posts Downbeat Earnings, Joins Vince Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session
↗
October 13, 2025
Via
Benzinga
Why Scholar Rock Stock Raced 6% Higher Today
↗
October 09, 2025
A pundit at an influential U.S. bank is quite bullish on the company's future.
Via
The Motley Fool
This Oracle Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday
↗
October 09, 2025
Via
Benzinga
Crinetics Pharmaceuticals, BlackBerry, Perpetua Resources And Other Big Stocks Moving Higher On Friday
↗
September 26, 2025
U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday. Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) rose sharply during Friday's session after the FDA...
Via
Benzinga
Topics
Stocks
Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection
↗
September 23, 2025
FDA cites Catalent Indiana issues in Scholar Rock's SMA drug review; European approval decision expected in 2026, with Germany as the launch market.
Via
Benzinga
Scholar Rock, A Top 10% Stock, Dives After Catalent Issues Hamper SMA Drug
↗
September 23, 2025
Shares tumbled Tuesday after the FDA rejected the company's spinal muscular atrophy drug.
Via
Investor's Business Daily
Firefly Aerospace Posts Q2 Results, Joins Scholar Rock And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
↗
September 23, 2025
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
September 23, 2025
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
↗
September 22, 2025
Via
Benzinga
Curious about the stocks that are showing activity after the closing bell on Monday?
↗
September 22, 2025
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Via
Chartmill
Why Scholar Rock Stock Bounced Higher on Monday
↗
September 15, 2025
One pundit believes the share price could rise in excess of 50%.
Via
The Motley Fool
How Do Investors Really Feel About Scholar Rock Holding?
↗
September 08, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
